Photo from wikipedia
To the editor, Recurrent hepatocellular carcinoma (r‐HCC) develops in >30% of patients following liver transplantation (LT) and represents a negative predictor of survival.[1] Despite this, r‐HCC after LT lacks an… Click to show full abstract
To the editor, Recurrent hepatocellular carcinoma (r‐HCC) develops in >30% of patients following liver transplantation (LT) and represents a negative predictor of survival.[1] Despite this, r‐HCC after LT lacks an accepted gold‐ standard therapy supported by prospective randomized evidence. Several small studies have examined the role of locoregional therapies (LRTs) in r‐HCC after LT, but there is a lack of studies examining transarterial radioembolization (TARE) in this patient population. This multicenter retrospective study aims to explore the utility of TARE with yttrium‐90 (Y90) for treating patients with r‐HCC after LT.
Journal Title: Liver Transplantation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!